Axogen Inc (NASDAQ:AXGN) — Market Cap & Net Worth
Market Cap & Net Worth: Axogen Inc (AXGN)
Axogen Inc (NASDAQ:AXGN) has a market capitalization of $1.75 Billion ($1.75 Billion) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6758 globally and #1983 in its home market, demonstrating a 15.69% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Axogen Inc's stock price $43.28 by its total outstanding shares 50169216 (50.17 Million). Analyse Axogen Inc (AXGN) cash flow conversion to see how efficiently the company converts income to cash.
Axogen Inc Market Cap History: 2015 to 2026
Axogen Inc's market capitalization history from 2015 to 2026. Data shows growth from $250.85 Million to $2.17 Billion (23.45% CAGR).
Index Memberships
Axogen Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.07% | #175 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #727 of 3165 |
Weight: Axogen Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Axogen Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Axogen Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.41x
Axogen Inc's market cap is 4.41 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $250.85 Million | $27.33 Million | -$13.36 Million | 9.18x | N/A |
| 2016 | $451.52 Million | $41.11 Million | -$14.41 Million | 10.98x | N/A |
| 2017 | $1.42 Billion | $60.43 Million | -$10.45 Million | 23.50x | N/A |
| 2018 | $1.02 Billion | $83.94 Million | -$22.40 Million | 12.21x | N/A |
| 2019 | $897.53 Million | $106.71 Million | -$29.12 Million | 8.41x | N/A |
| 2020 | $898.03 Million | $112.30 Million | -$23.79 Million | 8.00x | N/A |
| 2021 | $470.09 Million | $127.36 Million | -$26.98 Million | 3.69x | N/A |
| 2022 | $500.69 Million | $138.58 Million | -$28.95 Million | 3.61x | N/A |
| 2023 | $342.66 Million | $159.01 Million | -$21.72 Million | 2.15x | N/A |
| 2024 | $826.79 Million | $187.34 Million | -$9.96 Million | 4.41x | N/A |
Competitor Companies of AXGN by Market Capitalization
Companies near Axogen Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Axogen Inc by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #141 globally with a market cap of $155.56 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #208 globally with a market cap of $112.79 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #230 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #236 globally with a market cap of $102.56 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #141 | Abbott Laboratories | NYSE:ABT | $155.56 Billion | $89.46 |
| #208 | Stryker Corporation | NYSE:SYK | $112.79 Billion | $294.73 |
| #230 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #236 | Medtronic PLC | NYSE:MDT | $102.56 Billion | $80.00 |
Axogen Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Axogen Inc's market cap moved from $250.85 Million to $ 2.17 Billion, with a yearly change of 23.45%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.17 Billion | +32.23% |
| 2025 | $1.64 Billion | +98.60% |
| 2024 | $826.79 Million | +141.29% |
| 2023 | $342.66 Million | -31.56% |
| 2022 | $500.69 Million | +6.51% |
| 2021 | $470.09 Million | -47.65% |
| 2020 | $898.03 Million | +0.06% |
| 2019 | $897.53 Million | -12.43% |
| 2018 | $1.02 Billion | -27.81% |
| 2017 | $1.42 Billion | +214.44% |
| 2016 | $451.52 Million | +80.00% |
| 2015 | $250.85 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Axogen Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.75 Billion USD |
| MoneyControl | $1.75 Billion USD |
| MarketWatch | $1.75 Billion USD |
| marketcap.company | $1.75 Billion USD |
| Reuters | $1.75 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Axogen Inc
Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porc… Read more